Pembrolizumab is a humanized monoclonal antibody of the IgG4-kappa subclass that functions as an immune checkpoint inhibitor by targeting the programmed death-1 (PD-1) receptor. This immunotherapy is indicated… Read more
Pembrolizumab is a humanized monoclonal antibody of the IgG4-kappa subclass that functions as an immune checkpoint inhibitor by targeting the programmed death-1 (PD-1) receptor. This immunotherapy is indicated for the treatment of various malignancies, including metastatic melanoma, non-small cell lung cancer, and Hodgkin lymphoma, by blocking PD-1-mediated immune suppression to restore T-cell antitumor activity. The reference standards, impurities, metabolites, and stable isotope labelled compounds provided in this category serve as critical tools for pharmaceutical laboratories and researchers. These materials are essential for conducting comprehensive analytical testing, method validation, and quality control throughout the product lifecycle. Utilizing these standards enables precise impurity profiling and ensures reliable bioanalysis and consistency in characterization. By employing these materials, analytical scientists can maintain rigorous regulatory alignment and verify the stability and integrity of pembrolizumab in complex biopharmaceutical applications.